Market Overview:
The global progressive multifocal leukoencephalopathy (PML) drug market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing incidence of PML, rising demand for better treatment options, and growing awareness about PML. Based on type, the global PML drug market is segmented into EBT-103, IKT-01427, Imatinib Mesylate, NI-307 and others. The EBT-103 segment is expected to account for a major share of the global PML drug market during the forecast period. This can be attributed to its high efficacy and safety profile. Based on application, the hospital segment is expected to account for a major share of the global PML drug market during the forecast period. This can be attributed to increasing number of patients with advanced stage cancer being treated in hospitals.
Product Definition:
Progressive Multifocal Leukoencephalopathy Drug is a medication that is used to treat Progressive Multifocal Leukoencephalopathy. This drug helps to improve the symptoms of Progressive Multifocal Leukoencephalopathy and can help to improve the quality of life for those who are suffering from this condition.
EBT-103:
Progressive multifocal leukoencephalopathy (PML) is a rare disorder that affects the white matter of the brain, leading to multiple brain tumors. PML has been reported in 2-3 cases per million annually in U.S., with a prevalence of 1 case per 100,000 adults. The incidence rate is higher among African Americans (4-5 times higher than average), and women are generally affected twice as often as men (1.5 times).
IKT-01427:
IKT-01427 is a drug developed by Ionis Pharmaceuticals for the treatment of Progressive Multifocal Leukoencephalopathy (PML) which is also known as variant of chronic granulomatous disease. It was granted Fast Track designation by the FDA for its clinical efficacy and safety in PML patients. IKT-01427 has completed phase 2 clinical trial and received Orphan Drug Designation from both U.S.
Application Insights:
The hospital application segment dominated the global market in 2017. The rising prevalence of cancer and increasing number of patients suffering from PMF is driving the demand for these drugs in hospital settings. In addition, a rise in healthcare spending along with growing awareness about PMF is expected to fuel market growth over the forecast period.
Clinic applications are anticipated to witness significant growth over the forecast period owing to an increase in incidence rates of multiple sclerosis and other demyelinating diseases which require long-term treatment with antifungal drugs. According to data published by WHO, approximately 100 million people globally suffer from some form of arthritis; this number is projectededto reach 300 million by 2050 if effective measures are not taken against it (1). This scenario encourages manufacturers towards developing new products for clinics that offer faster relief from pain without having any negative effects on neurological health as compared to regular doses at hospitals or pharmacies.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers, suppliers, and consumers is one of the major factors contributing to its dominance. In addition, increasing R&D activities for drug development and introduction of novel formulations are also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising incidences associated with this condition coupled with growing healthcare expenditure in emerging economies such as India and China. Moreover, availability of raw materials including germanium for EBT-103 production at low cost will also contribute towards regional expansion over the next eight years (2018 - 2030).
Growth Factors:
- Increasing incidence of progressive multifocal leukoencephalopathy (PML)
- Growing demand for better treatment options for PML patients
- Rising awareness about PML and its symptoms among people
- Availability of government funding for research on PML drugs
- Technological advancements in the field of drug development
Scope Of The Report
Report Attributes
Report Details
Report Title
Progressive Multifocal Leukoencephalopathy Drug Market Research Report
By Type
EBT-103, IKT-01427, Imatinib Mesylate, NI-307, Others
By Application
Hospital, Clinic, Research Center
By Companies
Excision BioTherapeutics Inc, Humabs BioMed SA, Neurimmune Holding AG, Neuway Pharma GmbH, Pomona Ricerca SRL, Excision BioTherapeutics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Progressive Multifocal Leukoencephalopathy Drug Market Report Segments:
The global Progressive Multifocal Leukoencephalopathy Drug market is segmented on the basis of:
Types
EBT-103, IKT-01427, Imatinib Mesylate, NI-307, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Research Center
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Excision BioTherapeutics Inc
- Humabs BioMed SA
- Neurimmune Holding AG
- Neuway Pharma GmbH
- Pomona Ricerca SRL
- Excision BioTherapeutics Inc
Highlights of The Progressive Multifocal Leukoencephalopathy Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- EBT-103
- IKT-01427
- Imatinib Mesylate
- NI-307
- Others
- By Application:
- Hospital
- Clinic
- Research Center
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Progressive Multifocal Leukoencephalopathy Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Progressive multifocal leukoencephalopathy (PML) is a rare and serious brain disease caused by the accumulation of abnormal proteins in the brain. PML can cause serious vision problems, including blindness, and can lead to death. There is no known cure for PML, but there are treatments that may help improve symptoms.
Some of the major companies in the progressive multifocal leukoencephalopathy drug market are Excision BioTherapeutics Inc, Humabs BioMed SA, Neurimmune Holding AG, Neuway Pharma GmbH, Pomona Ricerca SRL, Excision BioTherapeutics Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Progressive Multifocal Leukoencephalopathy Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Progressive Multifocal Leukoencephalopathy Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Progressive Multifocal Leukoencephalopathy Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Progressive Multifocal Leukoencephalopathy Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Progressive Multifocal Leukoencephalopathy Drug Market Size & Forecast, 2020-2028 4.5.1 Progressive Multifocal Leukoencephalopathy Drug Market Size and Y-o-Y Growth 4.5.2 Progressive Multifocal Leukoencephalopathy Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 EBT-103
5.2.2 IKT-01427
5.2.3 Imatinib Mesylate
5.2.4 NI-307
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Research Center
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Progressive Multifocal Leukoencephalopathy Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Progressive Multifocal Leukoencephalopathy Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 EBT-103
9.6.2 IKT-01427
9.6.3 Imatinib Mesylate
9.6.4 NI-307
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Research Center
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 EBT-103
10.6.2 IKT-01427
10.6.3 Imatinib Mesylate
10.6.4 NI-307
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Research Center
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 EBT-103
11.6.2 IKT-01427
11.6.3 Imatinib Mesylate
11.6.4 NI-307
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Research Center
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 EBT-103
12.6.2 IKT-01427
12.6.3 Imatinib Mesylate
12.6.4 NI-307
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Research Center
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 EBT-103
13.6.2 IKT-01427
13.6.3 Imatinib Mesylate
13.6.4 NI-307
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Research Center
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Progressive Multifocal Leukoencephalopathy Drug Market: Competitive Dashboard
14.2 Global Progressive Multifocal Leukoencephalopathy Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Excision BioTherapeutics Inc
14.3.2 Humabs BioMed SA
14.3.3 Neurimmune Holding AG
14.3.4 Neuway Pharma GmbH
14.3.5 Pomona Ricerca SRL
14.3.6 Excision BioTherapeutics Inc